Literature DB >> 10092962

Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test.

B J Ward1, S Aouchiche, N Martel, F M Bertley, N Bautista-Lopez, B Serhir, S Ratnam.   

Abstract

Plaque reduction neutralization (PRN) is the "gold-standard" for the measurement of measles-specific neutralizing antibodies. However, it is a complicated assay and tends to be operator-dependent. It has been suggested that the simpler syncytium inhibition assay (SIA) can give results comparable to the PRN test. We compared these two assays using 594 serum or plasma samples obtained from children at various times after natural infection, primary measles immunization, and measles revaccination. The results of the two assays correlated well overall (r = .86; p < 0.0001). The strain of challenge virus (wild-type versus vaccine strain) did not significantly influence SIA titers and the assay performed equally well with serum and plasma. PRN titers > or = 120 and > 800 are thought to indicate protection against clinical illness and infection respectively. The equivalent SIA cut-off values using 125 plaque-forming units as the challenge inoculum were > or = 16 and > 128 respectively. At low PRN titers (< 200), the correlation between PRN and SIA values was reasonable (r = 0.60; p < 0.001) when a challenge inoculum of 12.5 plaque-forming units was used. At the lowest PRN titers (< 100), 15% of the samples gave divergent results. These data confirm the utility of the SIA in the determination of measles-specific neutralizing antibodies when antibody titers are high. However, the PRN assay remains the test of choice when maximum sensitivity at low titers is required.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092962     DOI: 10.1016/s0732-8893(98)00069-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

1.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Authors:  Masae Itoh; Yoshinobu Okuno; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

4.  Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.

Authors:  Ianko D Iankov; Pavlos Msaouel; Cory Allen; Mark J Federspiel; Peggy A Bulur; Allan B Dietz; Dennis Gastineau; Yasuhiro Ikeda; James N Ingle; Stephen J Russell; Evanthia Galanis
Journal:  Breast Cancer Res Treat       Date:  2009-11-06       Impact factor: 4.872

5.  Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

6.  Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.

Authors:  Ianko D Iankov; Alan R Penheiter; Guy E Griesmann; Stephanie K Carlson; Mark J Federspiel; Evanthia Galanis
Journal:  Virus Res       Date:  2012-12-21       Impact factor: 3.303

7.  Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Authors:  Ianko D Iankov; Mark J Federspiel; Evanthia Galanis
Journal:  Vaccine       Date:  2013-08-12       Impact factor: 3.641

8.  A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses.

Authors:  Inna G Ovsyannikova; Daniel J Schaid; Beth R Larrabee; Iana H Haralambieva; Richard B Kennedy; Gregory A Poland
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

9.  Assessment of measles immunity among infants in Maputo City, Mozambique.

Authors:  Jagrati V Jani; Carol Holm-Hansen; Tufária Mussá; Arlinda Zango; Ivan Manhiça; Gunnar Bjune; Ilesh V Jani
Journal:  BMC Public Health       Date:  2008-11-12       Impact factor: 3.295

10.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.